ValuEngine Lowers Aimmune Therapeutics (NASDAQ:AIMT) to Buy

ValuEngine lowered shares of Aimmune Therapeutics (NASDAQ:AIMT) from a strong-buy rating to a buy rating in a report issued on Friday, ValuEngine reports.

Other equities research analysts have also recently issued reports about the stock. Royal Bank of Canada decreased their price target on shares of Aimmune Therapeutics to $50.00 and set an outperform rating on the stock in a research note on Friday, August 9th. Piper Jaffray Companies set a $60.00 price target on shares of Aimmune Therapeutics and gave the stock a buy rating in a research note on Wednesday, October 9th. Goldman Sachs Group set a $27.00 price target on shares of Aimmune Therapeutics and gave the stock a hold rating in a research note on Friday, October 25th. BidaskClub raised shares of Aimmune Therapeutics from a sell rating to a hold rating in a research note on Monday, November 25th. Finally, Zacks Investment Research raised shares of Aimmune Therapeutics from a sell rating to a hold rating in a research note on Thursday, November 7th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $43.11.

Aimmune Therapeutics stock opened at $27.89 on Friday. Aimmune Therapeutics has a 12-month low of $16.95 and a 12-month high of $29.68. The stock has a market capitalization of $1.75 billion, a P/E ratio of -7.60 and a beta of -0.03. The firm’s 50-day moving average is $27.26 and its two-hundred day moving average is $22.19. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.64 and a quick ratio of 4.64.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($1.03). During the same quarter last year, the firm earned ($0.89) EPS. As a group, analysts forecast that Aimmune Therapeutics will post -3.97 EPS for the current year.

In related news, CFO Eric Bjerkholt bought 1,550 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were acquired at an average cost of $22.57 per share, with a total value of $34,983.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 13.75% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers boosted its position in shares of Aimmune Therapeutics by 0.7% in the third quarter. Rhumbline Advisers now owns 63,890 shares of the biotechnology company’s stock worth $1,338,000 after acquiring an additional 462 shares during the last quarter. California State Teachers Retirement System boosted its position in shares of Aimmune Therapeutics by 1.2% in the third quarter. California State Teachers Retirement System now owns 69,230 shares of the biotechnology company’s stock worth $1,450,000 after acquiring an additional 827 shares during the last quarter. Virtus ETF Advisers LLC boosted its position in shares of Aimmune Therapeutics by 11.2% in the second quarter. Virtus ETF Advisers LLC now owns 13,338 shares of the biotechnology company’s stock worth $278,000 after acquiring an additional 1,345 shares during the last quarter. Marshall Wace North America L.P. acquired a new stake in shares of Aimmune Therapeutics in the first quarter worth approximately $32,000. Finally, Tower Research Capital LLC TRC acquired a new stake in shares of Aimmune Therapeutics in the third quarter worth approximately $38,000. 81.82% of the stock is currently owned by institutional investors and hedge funds.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

Further Reading: Trade War

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.